Skip to main content

RETRACTION article

Front. Oncol., 22 February 2024
Sec. Cancer Imaging and Image-directed Interventions
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1383375

Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

This article is a retraction of:

  1. RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    A Retraction of the Original Research Article
    A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

    by Yang Q, Li G, Wu X, Lin H, Wu W, Xie X, Zhu Y, Cai W, Shi C and Zhuo S (2023) Front. Oncol. 13:1136366. doi: 10.3389/fonc.2023.1136366

    The journal retracts the 2023 article cited above.

    Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers’ policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

    The authors have not responded to this retraction.

    This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.

    Citation: Frontiers Editorial Office (2024) Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma. Front. Oncol. 14:1383375. doi: 10.3389/fonc.2024.1383375

    Received: 07 February 2024; Accepted: 10 February 2024;
    Published: 22 February 2024.

    Approved by:

    Frontiers Editorial Office, Frontiers Media SA, Switzerland

    Copyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.